VelocityShares 3x Inverse Gold ETN (DGLD) At $49.47 Forms Bottom; Array Biopharma (ARRY) Shorts Down By 10.22%

June 30, 2018 - By Shannon Black

Array BioPharma Inc. (NASDAQ:ARRY) Logo

VelocityShares 3x Inverse Gold ETN (DGLD) formed multiple bottom with $47.00 target or 5.00% below today’s $49.47 share price. VelocityShares 3x Inverse Gold ETN (DGLD) has $16.72M valuation. The stock decreased 1.04% or $0.52 during the last trading session, reaching $49.47. About 88,404 shares traded or 23.68% up from the average. VelocityShares 3x Inverse Gold ETN (NASDAQ:DGLD) has declined 10.27% since June 30, 2017 and is downtrending. It has underperformed by 22.84% the S&P500.

Array Biopharma Inc (NASDAQ:ARRY) had a decrease of 10.22% in short interest. ARRY’s SI was 13.63 million shares in June as released by FINRA. Its down 10.22% from 15.19 million shares previously. With 3.20M avg volume, 4 days are for Array Biopharma Inc (NASDAQ:ARRY)’s short sellers to cover ARRY’s short positions. The SI to Array Biopharma Inc’s float is 8.28%. The stock decreased 0.71% or $0.12 during the last trading session, reaching $16.78. About 3.16 million shares traded or 14.74% up from the average. Array BioPharma Inc. (NASDAQ:ARRY) has risen 92.14% since June 30, 2017 and is uptrending. It has outperformed by 79.57% the S&P500. Some Historical ARRY News: 09/04/2018 – MERCK & CO INC – SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT; 25/04/2018 – EC OKS BRISTOL-MYERS SQUIBB’S OPDIVO (NIVOLUMAB) FOUR-WEEK DOSI; 06/03/2018 Bristol-Myers Squibb’s Opdivo(R) (nivolumab) Now The First And Only FDA-Approved PD-1 Inhibitor To Offer Every Four-Week Dosing; 02/04/2018 – Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials; 22/03/2018 – BerGenBio to Present Overview of Phase Il Clinical Trial Portfolio Combining Bemcentinib With KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe; 16/04/2018 – OVERALL RESPONSE RATE 45.3 PCT FOR OPDIVO PLUS YERVOY VS 27 PCT FOR CHEMOTHERAPY – DATA; 06/03/2018 – BRISTOL-MYERS SQUIBB SAYS FDA APPROVES OPDIVO LABEL UPDATE; 16/04/2018 – FDA OKS BRISTOL-MYERS’ NIVOLUMAB PLUS IPILIMUMAB COMBINATION; 16/04/2018 – OPDIVO 1-YEAR PROGRESSION-FREE SURVIVAL RATE `SUPERIOR BENEFIT’; 03/05/2018 – BMY: EMA VALIDATED TYPE II VARIATION APPLICATION FOR OPDIVO

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $3.53 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

Since January 16, 2018, it had 0 insider buys, and 11 selling transactions for $6.95 million activity. Another trade for 7,500 shares valued at $102,975 was made by Haddock Jason on Tuesday, January 16. $278,210 worth of Array BioPharma Inc. (NASDAQ:ARRY) was sold by VAN LUNSEN GIL J on Wednesday, January 17. 77,576 shares were sold by Sandor Victor, worth $1.46 million on Tuesday, June 19.

More news for Array BioPharma Inc. (NASDAQ:ARRY) were recently published by: Benzinga.com, which released: “Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking” on June 28, 2018. Seekingalpha.com‘s article titled: “Key events next week – healthcare” and published on June 21, 2018 is yet another important article.

Among 7 analysts covering Array Biopharma (NASDAQ:ARRY), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Array Biopharma has $33 highest and $17.0 lowest target. $23.14’s average target is 37.90% above currents $16.78 stock price. Array Biopharma had 13 analyst reports since January 21, 2018 according to SRatingsIntel. Cowen & Co maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Thursday, May 10. Cowen & Co has “Buy” rating and $1900 target. Wells Fargo maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Thursday, June 28. Wells Fargo has “Outperform” rating and $33 target. The company was maintained on Monday, June 25 by Cantor Fitzgerald. Stifel Nicolaus maintained it with “Buy” rating and $23.0 target in Tuesday, February 6 report. The firm earned “Buy” rating on Wednesday, February 7 by Cowen & Co. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Cowen & Co on Tuesday, June 5. Leerink Swann maintained it with “Outperform” rating and $20 target in Wednesday, February 7 report. Cowen & Co maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Sunday, January 21. Cowen & Co has “Buy” rating and $17.0 target. Stifel Nicolaus maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Sunday, January 21. Stifel Nicolaus has “Buy” rating and $20.0 target. The firm has “Buy” rating given on Monday, June 25 by Piper Jaffray.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Chart